000307633 001__ 307633
000307633 005__ 20260115152727.0
000307633 0247_ $$2doi$$a10.1136/jitc-2025-014090
000307633 0247_ $$2pmid$$apmid:41529910
000307633 037__ $$aDKFZ-2026-00104
000307633 041__ $$aEnglish
000307633 082__ $$a610
000307633 1001_ $$0P:(DE-He78)7bf2f090fe39a6cd6f0bccf5ea2d4fb3$$aBecker, Jürgen$$b0$$udkfz
000307633 245__ $$aMerkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockade.
000307633 260__ $$aLondon$$bBioMed Central$$c2026
000307633 3367_ $$2DRIVER$$aarticle
000307633 3367_ $$2DataCite$$aOutput Types/Journal article
000307633 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1768487224_984431$$xReview Article
000307633 3367_ $$2BibTeX$$aARTICLE
000307633 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307633 3367_ $$00$$2EndNote$$aJournal Article
000307633 500__ $$a#DKTKZFB26#
000307633 520__ $$aMerkel cell carcinoma (MCC) exemplifies the paradigm of immunogenic tumors that nonetheless develop sophisticated immune evasion mechanisms. This is in line with the observation that MCC exhibits remarkable susceptibility to immune checkpoint inhibitors (ICIs), with responses in approximately half of patients with advanced disease in the first-line setting. However, 40-50% of patients show primary ICI resistance, while 20-30% of patients develop acquired ICI resistance on initial disease control. Still, the advent of ICI therapy represents a revolutionary rather than evolutionary advance in MCC management, fundamentally transforming outcomes from the dismal prognosis associated with conventional chemotherapy to durable responses extending substantially beyond 2 years. Still, important questions remain: (1) Is programmed cell death protein-1 or programmed death-ligand 1 inhibition more effective? (2) How long should ICI treatment continue? (3) What is the best choice of salvage therapy for patients with primary or acquired ICI resistance? (4) Which combination regimens can increase the share of patients benefiting from ICI? (5) Which patient/tumor characteristics predict response and its duration? Finally, (6) which timing of ICI therapy, that is, the neoadjuvant, adjuvant or therapeutic setting, offers the optimal overall outcomes for patients with MCC? A number of recent studies provide initial, but unfortunately not yet definitive answers.
000307633 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000307633 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307633 650_7 $$2Other$$aAdjuvant
000307633 650_7 $$2Other$$aBiomarker
000307633 650_7 $$2Other$$aImmune Checkpoint Inhibitor
000307633 650_7 $$2Other$$aImmunotherapy
000307633 650_7 $$2Other$$aNeoadjuvant
000307633 650_7 $$2NLM Chemicals$$aImmune Checkpoint Inhibitors
000307633 650_2 $$2MeSH$$aHumans
000307633 650_2 $$2MeSH$$aCarcinoma, Merkel Cell: drug therapy
000307633 650_2 $$2MeSH$$aCarcinoma, Merkel Cell: immunology
000307633 650_2 $$2MeSH$$aImmune Checkpoint Inhibitors: therapeutic use
000307633 650_2 $$2MeSH$$aImmune Checkpoint Inhibitors: pharmacology
000307633 650_2 $$2MeSH$$aImmunotherapy: methods
000307633 650_2 $$2MeSH$$aSkin Neoplasms: drug therapy
000307633 650_2 $$2MeSH$$aSkin Neoplasms: immunology
000307633 7001_ $$00000-0002-6930-2694$$aLodde, Georg$$b1
000307633 7001_ $$00000-0002-6720-7570$$aHaist, Maximilian$$b2
000307633 7001_ $$aUgurel, Selma$$b3
000307633 773__ $$0PERI:(DE-600)2719863-7$$a10.1136/jitc-2025-014090$$gVol. 14, no. 1, p. e014090 -$$n1$$pe014090$$tJournal for ImmunoTherapy of Cancer$$v14$$x2051-1426$$y2026
000307633 909CO $$ooai:inrepo02.dkfz.de:307633$$pVDB
000307633 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7bf2f090fe39a6cd6f0bccf5ea2d4fb3$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000307633 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000307633 9141_ $$y2026
000307633 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ IMMUNOTHER CANCER : 2022$$d2024-12-11
000307633 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000307633 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000307633 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-01-24T13:16:43Z
000307633 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-01-24T13:16:43Z
000307633 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-01-24T13:16:43Z
000307633 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-11
000307633 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-11
000307633 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000307633 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000307633 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000307633 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000307633 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ IMMUNOTHER CANCER : 2022$$d2024-12-11
000307633 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-11
000307633 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-11
000307633 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000307633 980__ $$ajournal
000307633 980__ $$aVDB
000307633 980__ $$aI:(DE-He78)ED01-20160331
000307633 980__ $$aUNRESTRICTED